<?xml version="1.0" encoding="UTF-8"?>
<ref id="B79-vaccines-08-00531">
 <label>79.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gallardo</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Sánchez</surname>
    <given-names>E.G.</given-names>
   </name>
   <name>
    <surname>Pérez-Núñez</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Nogal</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>De León</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Carrascosa</surname>
    <given-names>A.L.</given-names>
   </name>
   <name>
    <surname>Nieto</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Soler</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Arias</surname>
    <given-names>M.L.</given-names>
   </name>
   <name>
    <surname>Revilla</surname>
    <given-names>Y.</given-names>
   </name>
  </person-group>
  <article-title>African swine fever virus (ASFV) protection mediated by NH/P68 and NH/P68 recombinant live-attenuated viruses</article-title>
  <source>Vaccine</source>
  <year>2018</year>
  <volume>36</volume>
  <fpage>2694</fpage>
  <lpage>2704</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.03.040</pub-id>
  <?supplied-pmid 29609966?>
  <pub-id pub-id-type="pmid">29609966</pub-id>
 </element-citation>
</ref>
